The objective of this article is to examine the safety of prostate biopsy and discuss the emerging role of MRI-ultrasound fusion technology in improving diagnostic accuracy.
INTRODUCTION
Prostate cancer diagnosis is based on histologic examination of tissue routinely obtained via needle biopsy [1] . An estimated 1 million prostate biopsies are performed annually in the USA [2] . Although typically considered a safe procedure, prostate biopsy infrequently results in severe complications [3 & ]. In recent years, the incidence of infectious complications has increased significantly, which reflects the high prevalence of quinolone-resistant strains of Escherichia coli [2,3 & ,4]. Identifying high-risk men prior to biopsy and subsequently tailoring the selection of antibiotic prophylaxis has been shown to decrease the rate of infectious
. Transrectal ultrasound (TRUS)-guided prostate biopsy has for 3 decades been the standard for obtaining tissue for histological diagnosis, but several limitations of this method are now apparent [6,7 && ]. These limitations include frequent diagnosis of clinically insignificant prostate cancer and imprecise sampling, which misclassifies up to 50% of cases compared with radical prostatectomy specimen, and high-grade tumors missed in as many as 30% of cases [6,7 && ,8].
Over the past 6-8 years, multiparametric MRI (mpMRI) has gained widespread use to detect prostate cancer and guide prostate biopsy [9
DISCUSSION

Safety of prostate biopsy
Prostate biopsy is generally safe with few major, but frequent minor complications [17, 18] . Common complications include hematuria, infection, rectal bleeding, and hematospermia [17, 18] . In a European study of more than 7000 prostate biopsies, the most frequent complication was hematospermia, with an incidence of 53.8% [19] . Hematuria (24.3%), significant pain (4.8%), fever (4.1%), and hospital admission (0.7%) were less frequent [19] .
In recent years, there has been a significant increase in the number of infectious complications requiring hospital admission after prostate biopsy [2] . The significant increase in incidence of infectious complications has been attributed to an emergence of quinolone-resistant bacteria [20] . Rates of E. coli resistance to quinolones have been reported to be 12%, thus necessitating appropriate antibiotic selection in men undergoing prostate biopsy, especially in those at higher risk for infection [2, 21] .
Use of antibiograms to select antibiotic prophylaxis
Local antibiograms should be considered when selecting the appropriate prophylaxis because of the prevalent regional variation seen with antibiotic-resistance profiles [22 & ]. In our experience at the University of California at Los Angeles (UCLA), men with no significant risk factors for infection receive antibiotic prophylaxis with ciprofloxacin and ceftriaxone. Our current practice is based on the American Urological Association best practice policy statement, which recommends fluoroquinolone prophylaxis in men undergoing prostate biopsy [23] . In men identified as high risk (e.g., immunosuppression, recent antibiotic exposure, diabetes mellitus, or hospitalization), we administer both ciprofloxacin and ertapenem as antibiotic prophylaxis.
The antibiogram at UCLA reports bacterial susceptibilities from urine isolates within the local patient population. The five most common urine isolates are shown in the 2015 antibiogram (Table  1) . E.coli, which is only 78% susceptible to ciprofloxacin, is 93% susceptible to ceftriaxone and 99% susceptible to ertapenem. Following the dictates of the most current antibiogram allows us to modify antibiotic prophylaxis for high-risk patients on a contemporaneous basis. [25] . At UCLA, we augment antibiotic prophylaxis in every patient considered high risk, based on the above guidelines, thus allowing us to avoid the extra measure of rectal swab cultures.
Antibiotic prophylaxis for prostate biopsy
Transperineal biopsy
Transperineal biopsy is an alternative to the transrectal route, especially because of fewer infections [26, 27] . In a recent systematic review of 165 articles on the subject, transrectal biopsy was associated with higher rates of hospitalization (1.1 vs. 0.9%) and sepsis (0.8 vs. 0.1%) compared with transperineal biopsy, whereas urinary retention was more common using the transperineal approach (4.2 vs. 0.9%) [28 && ]. Transperineal biopsies are poorly tolerated in a clinic setting, thus general anesthesia is customarily used, which limits the widespread use of this approach. When whole organs are studied, Gleason score upgrading beyond biopsy findings is common [8, 32] . Cohen et al. [33] evaluated radical prostatectomy specimens of 2890 men diagnosed with prostate cancer via TRUS-guided biopsy. Of those men, 36% of radical prostatectomy specimens revealed a higher grade than previously diagnosed on initial biopsy [33] . ,37]. Using a similar scoring system, the likelihood of detecting csCaP in 825 men with at least grade 3 regions of interest (ROIs) at UCLA is shown in Fig. 1 , with a positive predictive value of 68 and 81% for PI-RADS 4 and 5 lesions to harbor csCaP, respectively.
Repeat biopsies
Use of MRI to detect prostate cancer
The accuracy of PI-RADS version 1.0 has been validated in a meta-analysis with a combined area Table 1 . Applying targeted biopsy cores in MRI suspicious lesions can be prone to a variety of targeting errors. In a cohort of 120 men who underwent radical prostatectomy after MRI-ultrasound fusion biopsy, 8% of the targeted biopsies missed the MRI suspicious lesion [14 && ]. Using rigid coregistration, Hadaschik [13] and Simpfendörfer [43] described a mean targeting error of 2-3 mm.
MRI-guided prostate biopsy
Suspicious lesions identified on mpMRI can be targeted during fusion biopsy [44] . Three methods of MRI-targeted biopsy exist: cognitive fusion, in-bore, and MRI-ultrasound fusion [44] . Cognitive fusion biopsy requires the operator to infer the location of suspicious lesions on MRI using TRUS images [45 & ]. In-bore biopsy is usually performed by a radiologist and involves targeting a suspicious lesion within the MRI tube [46] . Landmarks and targets for biopsy are defined using the preceding diagnostic mpMRI [47 & ]. MRI-ultrasound fusion biopsy utilizes registration or fusion software to identify and target a lesion on MRI during TRUS-guided biopsy [46] . ]. In contrast, 15 of the 28 men (54%) had csCaP on conventional systematic biopsy [11 && ]. The combination provided greater sensitivity in detection of csCaP than either alone. Figure 2 graphically displays current UCLAtargeted and systematic biopsy data in 320 men with a prior negative biopsy and persistently elevated prostate-specific antigen undergoing initial MRI-ultrasound fusion biopsy. Targeted biopsy diagnosed csCaP in 73 men compared with only 53 men diagnosed with csCaP using systematic biopsy alone. Combining the two methods diagnosed csCaP in 86 men.
Siddiqui et al. Screening for active surveillance Active surveillance is a favorable management strategy for many men with low-risk prostate cancer [50] . In 1994, the Epstein histological criteria were introduced to define clinically insignificant prostate cancer and determine eligibility for active surveillance [51] . Based on their results, clinically insignificant prostate cancer had no Gleason 4 disease, no more than two cores involved, and no core with greater than 50% involvement [51,52 && ]. The Epstein histological criteria were determined using biopsy specimens obtained on conventional TRUS biopsy [51] .
Hu ].
Using the Prostate Cancer Research International Active Surveillance protocol, data from the Heidelberg group report similar results [53] . Men whose active surveillance was based on an initial TRUSguided biopsy had a significantly higher probability of upgrading because of pathological progression on MRI-ultrasound fusion confirmatory biopsy, 
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FIGURE 2. The graph shows the number of patients with a prior negative biopsy and persistently elevated prostatespecific antigen diagnosed with significant and insignificant cancers depending on biopsy method. The combination of systematic and targeted biopsy results in detection of more clinically significant prostate cancer than either alone. Improved reflection of final pathology Gleason score concordance from conventional systematic biopsy to radical prostatectomy has been described as weak [33] . Shaw et al. 
